|
1
|
Mankin HJ, Hornicek FJ, Rosenberg AE,
Harmon DC and Gebhardt MC: Survival data for 648 patients with
osteosarcoma treated at one institution. Clin Orthop Relat Res.
429:286–291. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bramwell VHC: The role of chemotherapy in
osteogenic sarcoma. Crit Rev Oncol Hematol. 20:61–85. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bramwell VHC: The role of chemotherapy in
the management of non-metastatic operable extremity osteosarcoma.
Semin Oncol. 24:561–571. 1997.PubMed/NCBI
|
|
4
|
Liu L, Ning X, Sun L, Zhang H, Shi Y, Guo
C, et al: Hypoxia-inducible factor-1 alpha contributes to
hypoxia-induced chemoresistance in gastric cancer. Cancer Sci.
99:121–128. 2008.PubMed/NCBI
|
|
5
|
Quintero M, Mackenzie N and Brennan PA:
Hypoxia-inducible factor 1 (HIF-1α) in cancer. Eur J Surg Oncol.
30:465–468. 2004.
|
|
6
|
Russell DL, Ian S and Adrian L: The role
of hypoxia-inducible factor-1 in three dimensional tumor growth,
apoptosis and regulation by the insulin-signaling pathway. Cancer
Res. 65:4147–4152. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang QC, Zeng BF, Dong Y, Shi ZM, Jiang ZM
and Huang J: Overexpression of hypoxia-inducible factor-1a in human
osteosarcoma: correlation with clinicopathological parameters and
survival outcome. Jpn J Clin Oncol. 37:127–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mizobuchi H, Castellano JMG, Philip S,
Healey JH and Gorlick R: Hypoxia markers in human osteosarcoma: an
exploratory study. Clin Orthop Relat Res. 466:2052–2059. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu Q, Yang SH, Ye SN and Wang RY:
Therapeutic effects of RNA interference targeting HIF-1 alpha gene
on human osteosarcoma. Nail Med J Chin. 85:409–413. 2005.PubMed/NCBI
|
|
10
|
Cai W, Chen A, Guo F and Zhu B: Effects of
HIF-1α antisense oligonucleotides on the expression of HIF-1α and
VEGF in the osteosarcoma cell line MG-63. Chi J Clin Oncol. 33:1–5.
2006.
|
|
11
|
Ho QT and Kuo CJ: Vascular endothelial
growth factor: biology and therapeutic applications. Int J Biochem
Cell Biol. 39:1349–1357. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sak SC, Harnden P, Johnston CF, Paul AB
and Kiltie AE: APE1 and XRCC1 protein expression levels predict
cancer-specific survival following radical radiotherapy in bladder
cancer. Clin Cancer Res. 11:6205–6211. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang JL, Yang D, Cogdell D, Du XL, Li HX,
Pang Y, et al: APEX1 gene amplification and its protein
overexpression in osteosarcoma: correlation with recurrence,
metastasis and survival. Technol Cancer Res Treat. 9:161–169. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Geng YH, Wan CX and Chen PH: Expressions
of Cox-2 and HIF-lα and their relationship with clinicopathologic
characteristics of osteosarcoma. Tumor. 28:427–430. 2008.
|
|
15
|
Dickens S and Cripe TP: Effect of combined
cyclooxygenase-2 and matrix metalloproteinase inhibition on human
sarcoma xenografts. J Pediatr Hematol Oncol. 25:709–714. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Subbaramaiah K and Dannenberg AJ:
Cyclooxygenase 2: a molecular target for cancer prevention and
treatment. Trends Pharmacol Sci. 24:96–102. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
American Joint Committee on Cancer. AJCC
Cancer Staging Manual. Greene FL, Balch CM, Page DL, Haller DG,
Fleming ID, Morrow M and Fritz AG: 6th edition. Springer-Verlag;
New York: 2002, View Article : Google Scholar
|
|
18
|
Ferrari S and Palmerini E: Adjuvant and
neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr
Opin Oncol. 19:341–346. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rosen G, Caparros B, Huvos AG, et al:
Preoperative chemotherapy for osteogenic sarcoma: selection of
post-operative adjuvant chemotherapy based on the response of the
primary tumor to preoperative chemotherapy. Cancer. 49:1221–1230.
1982. View Article : Google Scholar
|
|
20
|
Kaya M, Wada T, Akatsuka T, et al:
Vascular endothelial growth factor expression in untreated
osteosarcoma is predictive of pulmonary metastasis and poor
prognosis. Clin Cancer Res. 6:572–577. 2000.PubMed/NCBI
|
|
21
|
Wu Q, Yang SH, Wang RY, Ye SN, Xia T and
Ma DZ: Effect of silencing HIF-1α by RNA interference on expression
of vascular endothelial growth factor in osteosarcoma cell line
SaOS-2 under hypoxia. Chin J Cancer. 24:531–535. 2005.
|
|
22
|
Bielack SS, Kempf-Bielack B, Delling G, et
al: Prognostic factors in high-grade osteosarcoma of the
extremities or trunk: an analysis of 1,702 patients treated on
neoadjuvant cooperative osteosarcoma study group protocols. J Clin
Oncol. 20:776–790. 2002. View Article : Google Scholar
|
|
23
|
Lee JA, Jung JS, Kim DH, et al: RANKL
expression is related to treatment outcome of patients with
localized, high-grade osteosarcoma. Pediatr Blood Cancer.
56:738–743. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li Y, Dang TA, Shen J, Hicks J,
Chintagumpala M, Lau CC, et al: Plasma proteome predicts
chemotherapy response in osteosarcoma patients. Oncol Rep.
25:303–314. 2011.PubMed/NCBI
|
|
25
|
Gougelet A, Pissaloux D, Besse A, Perez J,
Duc A, Dutour A, et al: Micro-RNA profiles in osteosarcoma as a
predictive tool for ifosfamide response. Int J Cancer. 129:680–690.
2011. View Article : Google Scholar : PubMed/NCBI
|
